Comparative study on efficacy and safety of ciprofol and medium-long chain propofol in painless gastroenteroscopy

Status

Recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2100050745

Enrollment

Unknown

Registered

2021-09-03

Start date

2021-10-01

Completion date

Unknown

Last updated

2022-05-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

anesthesia

Interventions

control group:Medium-long chain propofol

treatment group:ciprofol

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Select subjects for diagnosis and/or treatment by colonoscopy or gastroscopy; 2. Male or female, ASA grade I-II; 3. Aged >=18 and =18 and <=30 kg/m^2; 5. No sedation/general anesthesia contraindications.

Exclusion criteria

Exclusion criteria: 1. The recent history of taking sedative-hypnotic and anti-anxiety drugs and anti-depressant drugs; 2. Have a history of mental disorders and disorders of consciousness; 3. Those with severe cardiovascular and cerebrovascular, liver and kidney dysfunction; 4. Those with severe hearing and visual impairment; 5. Patients whose examination or treatment time exceeds 30 minutes, the treatment plan is changed in the middle, or the follow-up is lost; 6. Patients who cannot communicate with physicians normally and refuse to accept the study.

Design outcomes

Primary

Measure	Time frame
Blood pressure, heart rate and SpO2 ;Adverse reactions (nausea, vomiting; Respiratory depression; Intravenous pain; Postoperative mental disorder);Dosage of ciprofol and propofol;	—

Countries

China

Contacts

Public ContactYao Yipeng

Xiamen Hospital of Traditional Chinese Medicine

270665897@qq.com+86 15959262700

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026